Allopregnanolone Regenerative Therapeutic for Mild Alzheimer's Disease

Last updated: January 29, 2025
Sponsor: University of Arizona
Overall Status: Active - Recruiting

Phase

2

Condition

Multiple Sclerosis

Neurologic Disorders

Treatment

Placebo

Allopregnanolone

Clinical Study ID

NCT04838301
Allo-20-001
R01AG063826
  • Ages 55-80
  • All Genders

Study Summary

A phase 2, double-blind, randomized, placebo-controlled clinical trial to evaluate the safety and efficacy of Allopregnanolone as a regenerative therapeutic for Alzheimer's disease.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Men and postmenopausal women

  • Age 55 to 80 years old

  • Meets NIA-AA criteria for probable AD dementia

  • MMSE of 20-26

  • APOE ε4 positive

  • Geriatric Depression Scale short form (GDS-S) score of ≤ 6

  • No medical contraindications to participation

  • Capacity to provide informed consent at screening

Exclusion

Exclusion Criteria:

  • Dementia other than probable AD

  • Use of benzodiazepines, anticonvulsants, antipsychotics, or other drugs that mightinteract with the GABA-A receptor complex

  • History of stroke with a modified Hachinski Ischemic Scale score >4

  • History of seizure disorder, focal brain lesion, traumatic brain injury

  • History within the last 5 years of a primary or recurrent malignant disease

  • Unstable or clinically significant cardiovascular, kidney or liver disease

  • MRI indicative of any other significant abnormality, including but not limited toone or more significant ARIA-E or macro-hemorrhage findings, or multiplemicrohemorrhages (>8), or Fazekas score of 3; encephalomalacia, aneurysms, vascularmalformations, subdural hematoma, or space occupying lesions

  • Any conditions that would contraindicate MRI studies.

Study Design

Total Participants: 200
Treatment Group(s): 2
Primary Treatment: Placebo
Phase: 2
Study Start date:
August 15, 2023
Estimated Completion Date:
December 31, 2026

Study Description

This is a proof-of-concept phase 2 clinical trial to investigate the long-term safety and efficacy of Allo to function as a regenerative therapeutic to restore structural integrity and cognitive function of the brain in participants with mild Alzheimer's disease (AD) dementia. Study participants will be male and female, APOE ε4 positive diagnosed with probable AD, Mini-Mental State Exam (MMSE) 20 to 26, ages 55 to 80 years old.

After a 2-4-week screening period, participants will be randomized to 4 mg Allo (administered intravenously over 30 minutes, once per week, in clinic) or matching placebo, 1:1 allocation, for a period of 12 months. After 12 months, all participants in the placebo group will be crossed-over to receive Allo for the remainder of the study (6 month open-label phase). Brain imaging to evaluate the primary endpoint will be conducted at baseline, 6 and 12 months.

Connect with a study center

  • Perseverance Research Center

    Scottsdale, Arizona 85253
    United States

    Active - Recruiting

  • ATP Clinical Research

    Costa Mesa, California 92626
    United States

    Active - Recruiting

  • Wake Research

    Los Alamitos, California 90720
    United States

    Site Not Available

  • Syrentis Clinical Research

    Santa Ana, California 92705
    United States

    Active - Recruiting

  • Linfritz Research Institute inc

    Coral Gables, Florida 33134
    United States

    Site Not Available

  • Miami Jewish Health

    Miami, Florida 33137
    United States

    Active - Recruiting

  • Optimus U Corporation

    Miami, Florida 33135
    United States

    Active - Recruiting

  • Combined Research

    Orlando, Florida 32807
    United States

    Active - Recruiting

  • Conquest Research

    Winter Park, Florida 32789
    United States

    Active - Recruiting

  • MedVadis Research

    Waltham, Massachusetts 02451
    United States

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.